Northwest Biotherapeutics Financials
| NWBO Stock | USD 0.27 0.01 3.85% |
With this module, you can analyze Northwest financials for your investing period. You should be able to track the changes in Northwest Biotherapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Northwest |
The data published in Northwest Biotherapeutics' official financial statements typically reflect Northwest Biotherapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Northwest Biotherapeutics' quantitative information. For example, before you start analyzing numbers published by Northwest accountants, it's essential to understand Northwest Biotherapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Northwest Biotherapeutics Stock Summary
Northwest Biotherapeutics competes with Celldex Therapeutics, CEL SCI, Morningstar Unconstrained, Thrivent High, and Via Renewables. Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US66737P6007 |
| CUSIP | 66737P600 66737P105 66737P501 |
| Location | Maryland; U.S.A |
| Business Address | 4800 Montgomery Lane, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.nwbio.com |
| Phone | 240 497 9024 |
| Currency | USD - US Dollar |
Northwest Biotherapeutics Key Financial Ratios
Northwest Biotherapeutics' financial ratios allow both analysts and investors to convert raw data from Northwest Biotherapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Northwest Biotherapeutics over time and compare it to other companies across industries.| Return On Asset | -1.26 | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | -0.0115 | ||||
| Z Score | -0.6 |
Northwest Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Northwest Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Northwest Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Northwest Biotherapeutics competition to find correlations between indicators driving Northwest Biotherapeutics's intrinsic value. More Info.Northwest Biotherapeutics is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Northwest Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Northwest Biotherapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Northwest Biotherapeutics Systematic Risk
Northwest Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Northwest Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Northwest Biotherapeutics correlated with the market. If Beta is less than 0 Northwest Biotherapeutics generally moves in the opposite direction as compared to the market. If Northwest Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Northwest Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Northwest Biotherapeutics is generally in the same direction as the market. If Beta > 1 Northwest Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Northwest Biotherapeutics December 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Northwest Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Northwest Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Northwest Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Northwest OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Northwest Biotherapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 22.79 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 6.67 |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.